Patent Disputes Over COVID-19 Vaccines Expose Systemic Inequities in Global Health Governance
Original framing: “CureVac sues Moderna for patent infringement over COVID-19 vaccines - Reuters” — Reuters (via Google News)
Patent disputes over vaccines have a long history, dating back to the 19th century. The development of vaccines has always been a complex process involving multiple stakeholders, including pharmaceutical companies, governments, and civil society organizations. A deeper understanding of these historical patterns is essential to addressing the complexities of global health governance.
The patent dispute between CureVac and Moderna highlights the need for a more equitable and transparent global health governance system.
A system that prioritizes equitable access to health technologies, promotes transparency and accountability, and supports community-based health initiatives can help address the health needs of diverse populations. This requires a more inclusive and equitable approach to global health governance, one that takes into account the perspectives of low- and middle-income countries and marginalized communities within these countries. A deeper understanding of historical patterns and cross-cultural perspectives is essential to addressing the complexities of global health governance. By promoting transparency, accountability, and community-based health initiatives, we can create a more just and equitable global health system.